Man Group
LFCR icon

Man Group’s Lifecore Biomedical LFCR Stock Holding History

Man Group’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-38,714
Closed -$199K – 2099
2024
Q2 		$199K Sell
38,714
-60,410
-61% -$358K ﹤0.01% 1898
2024
Q1 		$526K Buy
99,124
+8,476
+9% +$60.6K ﹤0.01% 1765
2023
Q4 		$561K Buy
+90,648
New +$629K ﹤0.01% 1643

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Man Group's LFCR Position: Q3 2024 in Review

Man Group sold out of Lifecore Biomedical (LFCR) in Q3 2024, closing a stake of 38,714 shares — an estimated $199K sold.

Man Group first reported a position in LFCR in Q4 2023 and held it in 3 quarters. The position peaked at $561K in Q4 2023. 82 funds tracked by Wall St. Rank hold LFCR as of Q3 2024.

  • Man Group reported no remaining Lifecore Biomedical position as of Q3 2024 after selling out during the quarter.
  • Man Group sold 38,714 Lifecore Biomedical shares in Q3 2024, an estimated $199K.
  • Man Group first reported a position in Lifecore Biomedical in Q4 2023 and held it in 3 quarters.
  • Man Group's Lifecore Biomedical position peaked at $561K in Q4 2023.
  • 82 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2024.

Based on Man Group's 13F filing for Q3 2024, filed 14 Nov 2024.